Clinical trials

7

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Study of [89Zr]-Oxine-NCR100 Injection for the Cellular Distribution

This clinical study is to evaluate the biodistribution of \[89Zr\]-Oxine-NCR100 injection in subjects with knee osteoarthritis after local injection and the kinetic behavior characteristics of zirconium-labeled cells at the injection site and various organs or tissues. It is a single-dose, open-label study in adult KOA subjects.

Participants needed: 6
Trial details
Phase: Phase 1Age: 40-70Biological sex: MaleType: InterventionalSponsor: Nuwacell Biotechnologies Co., Ltd.Updated: Aug 24, 2025
Eligibility criteria

Subjects who understand and voluntarily sign the Informed Consent Form(ICF) befo...

Subjects previously diagnosed with secondary knee osteoarthritis, or those diagn...

Status: Recruiting

A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease

The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.

Participants needed: 48
Trial details
Phase: Phase 1Age: 40-75Biological sex: AllType: InterventionalSponsor: Nuwacell Biotechnologies Co., Ltd.Updated: Aug 1, 2025Locations: 1
Eligibility criteria

Ages between 40 and 75 years; [+4]

Patients who have previously undergone brain surgery; [+5]

Status: Not yet recruiting

A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD

Evaluate the safety and efficacy of NCR102 injection in the treatment of SR-aGVHD patients who have failed second-line therapy.

Participants needed: 24
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Nuwacell Biotechnologies Co., Ltd.Updated: Apr 23, 2025
Eligibility criteria

Age>18 years and <70 years old (including threshold), gender not limited; [+5]

Subjects have lung disease, and investigators have determined that they are not... [+7]

Status: Not yet recruiting

A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease

The target of this trial is to evaluate the safety, tolerability and preliminary efficacy of NCR101 in the treatment of subjects with interstitial lung disease. The trial contains Single ascending dose(SAD) and Multiple ascending dose(MAD). Subjects will receive at least 1 dose of NCR101.

Participants needed: 30
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Nuwacell Biotechnologies Co., Ltd.Updated: Feb 13, 2025
Eligibility criteria

Age>18 years old (including threshold), gender not limited; [+5]

Individuals with a history of severe allergies or allergies to the main active i... [+5]

Status: Not yet recruiting

A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis( KOA)

This clinical study is to investigate the safety and efficacy of NCR100 injection in subjects with knee osteoarthritis (KOA). It contains two parts dose-escalating, and blind random study in adult KOA subjects.

Participants needed: 162
Trial details
Phase: Phase 1, Phase 2Age: 40-65Biological sex: AllType: InterventionalSponsor: Nuwacell Biotechnologies Co., Ltd.Updated: Dec 18, 2024
Eligibility criteria

Subjects who understand and voluntarily sign the Informed Consent Form(ICF) befo... [+4]

Subjects previously diagnosed of secondary knee osteoarthritis, or those diagnos... [+23]

Status: Not yet recruiting

A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia(AML) After Transplantation

A Trial to Evaluate the Safety and Efficacy of iNK in the Treatment of Subjects for Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation.

Participants needed: 15
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Nuwacell Biotechnologies Co., Ltd.Updated: Jun 4, 2024
Eligibility criteria

Bone marrow examination shows hematological recurrence; [+18]

Status: Not yet recruiting

A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor

This trial is to investigate the safety, efficacy of iNK in subjects with solid tumor. It is a dose escalation and extension trial.

Participants needed: 50
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Nuwacell Biotechnologies Co., Ltd.Updated: Feb 7, 2024
Eligibility criteria

≥18 years old. [+7]

Central nervous system metastasis or meningeal metastasis with clinical symptoms... [+10]